Revolution Medicines IncRVMD

Why is Revolution Medicines (RVMD) moving?

Q3 202627 Jun – 16 Sep 2026

▲3▼1

FDA approval turns Revolution Medicines into commercial-stage company

Daraxonrasib Phase 3 survival win Strong Phase 3 data for daraxonrasib in metastatic pancreatic cancer nearly doubled median overall survival, a major clinical win that supports a roughly $40 billion valuation and validates the company's RAS-targeted approach.
This was the key clinical catalyst that re-rated the stock during the quarter.
FDA approval of Rasonque In September the FDA approved daraxonrasib (Rasonque), the first RAS-targeted pancreatic cancer drug, making Revolution Medicines a commercial-stage company with real revenue potential and a first-mover position.
The approval is the single biggest new event, changing the company's business model.
Regulatory designations and funding Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and a Royalty Pharma deal fund the pipeline without dilution, while Parnassus Growth Equity initiated a position, signaling institutional confidence.
These developments de-risk the launch and strengthen the balance sheet without shareholder dilution.
Cost and pricing concerns A wider-than-expected Q2 loss and raised 2026 spending guidance (second time) cast doubt on profitability timing, while Rasonque's $39,800 monthly price raises insurer coverage and patient affordability concerns that could limit sales.
This is the main counterweight, showing the commercial path is not without financial and access risks.

September 202626 Aug – 16 Sep 2026

▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.
This is the single biggest new event of the period and the core reason RVMD is moving.
Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.
Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.
Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.
It answers how the company pays for its pipeline now that it has a product but still spends heavily.
Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.
It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

Latest26 Aug – 16 Sep 2026

▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.
This is the single biggest new event of the period and the core reason RVMD is moving.
Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.
Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.
Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.
It answers how the company pays for its pipeline now that it has a product but still spends heavily.
Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.
It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

July 202627 Jun – 6 Aug 2026

▲3▼1

RVMD Soars on Strong Phase 3 Data, Regulatory Wins, and Competitive Edge

Daraxonrasib Phase 3 Data Revolution Medicines reported strong Phase 3 results for daraxonrasib in metastatic pancreatic cancer, with median overall survival nearly doubling to 13.2 months from 6.7 months, supporting a ~$40B valuation and a $10B+ market opportunity.
This is the primary positive catalyst that drove the stock's surge during the period.
Regulatory Designations and NDA Acceptance The company received Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and FDA acceptance of the daraxonrasib NDA with a fast-review voucher, building regulatory momentum.
These regulatory milestones accelerate the path to market and boost investor confidence.
Competitor Erasca Legal Woes Erasca faces securities litigation and investigations over alleged misleading comparisons to RVMD's RMC-6236, erasing $2.8B in market cap, which strengthens RVMD's competitive position.
This weakens a rival and reinforces RVMD's leadership in the RAS cancer space.
Wider Q2 Loss and Raised Spending Guidance RVMD reported a wider-than-expected Q2 loss and raised 2026 spending guidance for the second time, raising doubts about how soon the company can reach profitability.
This is a counterweight that could pressure the stock despite positive pipeline news.

23 Jul – 6 Aug 2026

▲3▼1

FDA accepts daraxonrasib NDA, but rising costs test RVMD's valuation

FDA accepts daraxonrasib NDA The FDA accepted Revolution Medicines' application for daraxonrasib in metastatic pancreatic cancer, a key step toward approval. The drug also got a fast-review voucher. This raises the chance of a launch and future sales, supporting the stock.
This is the period's biggest new regulatory event and directly drives RVMD's potential revenue.
Druckenmiller's fund buys RVMD shares Billionaire Stanley Druckenmiller's family office bought 316,000 shares. A well-known investor buying in can boost confidence and attract other buyers, pushing the stock up. It also highlights the drug's strong survival data.
This is a new, specific event that can influence investor sentiment and demand for the stock.
Wider Q2 loss and higher expense guidance Revolution Medicines reported a bigger quarterly loss than expected and raised its 2026 spending forecast for the second time. Costs are climbing fast as it prepares for launch. This raises doubts about how soon it can become profitable, weighing on the stock.
This is the main new negative financial update and a real counterweight to the positive news.
Erasca legal probe continues Hagens Berman is investigating Erasca over alleged misleading claims about its drug, including flawed comparisons to RVMD's RMC-6236. This keeps pressure on a competitor and reinforces RVMD's competitive edge in RAS cancer drugs.
It is a new development in a competitive threat that benefits RVMD's relative position.

27 Jun – 17 Jul 2026

▲4

Revolution Medicines' cancer data and regulatory wins drive RVMD higher

Daraxonrasib Phase 3 survival data and $40B valuation Daraxonrasib nearly doubled median overall survival (13.2 vs 6.7 months) in previously treated metastatic pancreatic cancer, supporting a potential $10B+ opportunity and a ~$40B market value. This validates the pipeline and raises expectations for future revenue.
This is the core clinical catalyst that justifies RVMD's valuation and future revenue potential.
Zoldonrasib combination shows high response rates Phase 1/2 data for zoldonrasib plus chemo in RAS G12D pancreatic cancer showed 82% and 61% response rates in untreated patients, and 50% in previously treated patients. These results support ongoing Phase 3 trials and expand the pipeline's potential.
New positive data for a second drug candidate broadens the growth story and de-risks the pipeline.
Regulatory progress: Breakthrough Therapy, Orphan Drug, EMA accelerated review Daraxonrasib received Breakthrough Therapy and Orphan Drug designations, and the European Medicines Agency launched an accelerated review. The company is nearing completion of its New Drug Application to the FDA, setting the stage for a potential global launch.
Regulatory milestones shorten the path to market and increase the probability of approval, directly impacting future sales.
Erasca legal troubles weaken a competitor Erasca faces a securities class action over alleged improper comparisons to RVMD's RMC-6236 and a patient death, erasing $2.8B in market cap. This strengthens RVMD's competitive position and intellectual property standing in the RAS cancer space.
A weakened competitor reduces competitive pressure and reinforces RVMD's leadership, supporting its pricing power and market share.

Q2 202618 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

June 202618 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

18 Jun – 26 Jun 2026

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.
This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.
Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.
Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.
Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.
The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.